[1. Vail DM: Hematopoietic tumors. In: Textbook of Veterinary Internal Medicine, 5th edn. Eds Ettinger SJ and Feldman EC. Philadelphia: W. B. Saunders; 2000, 507–522.]Search in Google Scholar
[2. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G, Bocchini V: Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 2008, 22(4):976–84.]Search in Google Scholar
[3. Zandvliet M: Canine lymphoma: a review. Vet Q 2016, 36(2):76–104.]Search in Google Scholar
[4. Gavazza A, Lubas G, Valori E, Gugliucci B: Retrospective survey of malignant lymphoma cases in the dog: clinical, therapeutical and prognostic features. Vet Res Commun 2008, 32(1):291–293.]Search in Google Scholar
[5. Sozmen M, Tasca S, Carli E, De Lorenzi D, Furlanello T, Caldin M: Use of fine needle aspirates and flow cytometry for the diagnosis, classification, and immunophenotyping of canine lymphomas. J Vet Diagn Invest 2005, 17:323–330.]Search in Google Scholar
[6. Burton JH, Garrett-Mayer E, Thamm DH: Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol 2013, 11(4):306–315.]Search in Google Scholar
[7. Boyce KL, Kitchell BE: Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000, 36: 395–403.]Search in Google Scholar
[8. Marrington AM, Killick DR, Grant IA, Blackwood L: Toxicity associated with epirubicin treatments in a large case series of dogs. Vet Comp Oncol 2012, 10(2):113–23.]Search in Google Scholar
[9. Sirivisoot S, Teewasutrakul P, Techangamsuwan S, Tangkawattana S, Rungsipipat A: Monitoring minimal residual disease in canine lymphomas treated with modified L-COP or L-CHOP protocols. Acta Vet Hung 2018, 66(1):66–84.]Search in Google Scholar
[10. Mellanby RJ, Herrtage ME, Dobson JM: Treatment of canine lymphoma by veterinarians in first opinion practice in England. J Small Anim Pract 2002, 43:198–202.]Search in Google Scholar
[11. Mellanby RJ, Herrtage ME, Dobson JM: Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma. J Small Anim Pract 2002, 43(3):100–103.]Search in Google Scholar
[12. Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ: Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol 2011, 9(3):172–182.]Search in Google Scholar
[13. Tzannes S, Hammond MF, Murphy S, Sparkes A, Blackwood L: Owners ‘perception of their cats’ quality of life during COP chemotherapy for lymphoma. J Feline Med Surg 2008, 10(1): 73–81.]Search in Google Scholar
[14. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM: Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005, 19: 732–736.]Search in Google Scholar
[15. Ettinger SN: Principles of treatment for canine lymphoma. Clin Tech Small Anim Pract 2003, 8(2):92–7.]Search in Google Scholar
[16. Sindhur A, Ashok Kumar RN, Deepak C, Kumar Tiwari NP: Effect of doxorubicin on haematological and blood biochemical profile of healthy dogs. Haryana Vet 2019, 58(1):11–14.]Search in Google Scholar
[17. Legrand JJ, Bouchez C, Mimouni C, N'Guyen A, Bouchard J, Ameller T, Descotes J: Immunotoxic effects of cyclophosphamide and cyclosporine in the dog. J of Immunotoxicol 2013, 10(1): 90–95.]Search in Google Scholar
[18. Gavazza A, Sacchini F, Lubas G, Gugliucci B, Valori E: Clinical, laboratory, diagnostic and prognostic aspects of canine lymphoma: a retrospective study. Comp Clin Path 2009, 18(3): 291–299.]Search in Google Scholar
[19. Curran K, Thamm DH: Retrospective analysis for treatment of naive canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. Vet Comp Oncol 2016, 14: 147–155.]Search in Google Scholar
[20. Simon D, Nolte I, Eberle N, Abbrederis N, Killich M, Hirschberger J: Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006, 20(4): 948–954.]Search in Google Scholar
[21. Brønden LB, Flagstad A, Rutteman GR, Teske E: Study of dog and cat owners' perceptions of medical treatment for cancer. Vet Rec 2003, 152(3):77–80.]Search in Google Scholar
[22. Slater MR, Barton CL, Rogers KS, Peterson JL, Harris CK, Wallace K: Factors affecting treatment decisions and satisfaction of owners of cats with cancer. J Am Vet Med Assoc 1996, 208(8):1248–52.]Search in Google Scholar
[23. Milevoj N, Tozon N, Licen S, Lampreht Tratar U, Sersa, G, Cemazar M: Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer. Vet Med Sci 2020. 6(3):290–298.]Search in Google Scholar
[24. Faustino LC, Lallo MA: Quality of life and pain in dogs with early-stage mammary tumours. Acta Vet Hung 2015. 63(4): 451–457.]Search in Google Scholar
[25. Thornton LA, Cave N, Bridges JP, Stell AJ: Owner perceptions of their cat's quality of life when treated with a modified University of Wisconsin–Madison protocol for lymphoma. J Feline Med Surg 2018. 20(4): 356–361.]Search in Google Scholar
